A practical reference on receptor agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-16. Anything still debated is marked as such rather than presented as settled.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
纯度评价多采用反相高效液相色谱，流动相常加入三氟乙酸或甲酸作为离子对改性剂，检测波长设在二百一十四纳米或二百二十纳米。分子量确认依靠电喷雾电离质谱或基质辅助激光解吸电离质谱，实测值应与理论值在数 ppm 内吻合。肽图分析通过酶切后液相色谱串联质谱完成，用于核查序列与修饰位点。体积排阻色谱用于定量共价与非共价聚集体。生物基质浓度测定则采用免疫分析或液相色谱串联质谱。
肽类的主要降解路径包括天冬酰胺脱酰胺、甲硫氨酸氧化、天冬氨酸异构化以及由 β-折叠驱动的聚集，这些反应对 pH 与缓冲液种类较为敏感。磷酸盐、丙二醇与苯酚等辅料会影响局部微环境与界面行为。强制降解研究借助高温、强光、氧化剂与极端 pH 暴露来预测产物谱。关于长期室温存放的数据相对有限，超出标签条件的稳定性仍属开放问题，需要在具体制剂中通过实时与加速试验加以确认。
| Property | Value | Notes |
|---|---|---|
| Molecular formula (free base) | C187H291N45O59 | Approximate; salt and hydrate forms differ |
| Molecular weight | ~4113.6 Da | Varies with counterion and hydration |
| Appearance | White to off-white powder | Lyophilized research material |
| Solubility class | Freely soluble in water | As formulated; native peptide less stable near neutral pH |
| Typical storage | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
== History == β-Endorphin was discovered in camel pituitary extracts by C.H. Li and David Chung. The primary structure of β-endorphin was unknowingly determined 10 years earlier, when Li and colleagues analyzed the sequence of another neuropeptide produced in the pituitary gland, γ-lipotropin. They noticed that the C-terminus region of this neuropeptide was similar to that of some enkephalins, suggesting that it may have a similar function to these neuropeptides. The C-terminal sequence of γ-lipotropin turned out to be the primary sequence of the β-endorphin.
== History == The GCCA was formed in 2007 through the merger of two processor organizations and was joined by a number of other core partners that became part of the alliance. The merger was between the International Association of Refrigerated Warehouses (IARW) formed in 1891, the International Refrigerated Transportation Association (IRTA) formed in 1994.
=== Nanotechnology === The Culture has highly advanced nanotechnology, though descriptions of such technology in the books is limited. Many of the described uses are by or for Special Circumstances, but there are no indications that the use of nanotechnology is limited in any way. (In a passage in one of the books, there is a brief reference to the question of sentience when comparing the human brain or a "pico-level substrate".) One of the primary clandestine uses of nanotechnology is information gathering. The Culture likes to be in the know, and as described in Matter "they tend to know everything." Aside from its vast network of sympathetic allies and wandering Culture citizens one of the primary ways that the Culture keeps track of important events is by the use of practically invisible nanobots capable of recording and transmitting their observations. This technique is described as especially useful to track potentially dangerous people (such as ex-Special Circumstances agents). Via such nanotechnology, it is potentially possible for the Culture (or similarly advanced societies) to see everything happening on a given planet, orbital or any other habitat. The usage of such devices is limited by various treaties and agreements among the Involved. In addition, EDust assassins are potent Culture terror weapons, composed entirely of nano machines called EDust, or "Everything Dust." They are capable of taking almost any shape or form, including swarms of insects or entire humans or aliens, and possess powerful weaponry capable of levelling entire buildings.
==== Methods of biomedical waste incineration ==== The three type of medical waste incinerators are controlled air, excess air, and rotary kiln. Controlled air is also known as starved-air incineration, two-stage incineration, or modular combustion. This is the process of which waste is fed to a combustion chamber and combustion air begins to dry and facilitates volatilization of the waste. As a result, carbon dioxide and other excess gases are released into the atmosphere. The second type of incineration is the excess air process. This is similar to the controlled air process, such as the waste being dried, ignited, and combusted by heat provided by the primary chamber burner. However, the main difference is that moisture and volatile components in the waste are vaporized. In a rotary kiln, the process is similar to the two mention above, however, it is more versatile in terms of being able to mix wet and dry waste components and viewed by many waste engineers as being the most environmentally friendly.
Sources: en.wikipedia.org
The chief characteristic of proteins that allows their diverse set of functions is their ability to bind other molecules specifically and tightly. The region of the protein responsible for binding another molecule is known as the binding site and is often a depression or "pocket" on the molecular surface. This binding ability is mediated by the tertiary structure of the protein, which defines the binding site pocket, and by the chemical properties of the surrounding amino acids' side chains. Protein binding can be extraordinarily tight and specific; for example, the ribonuclease inhibitor protein binds to human angiogenin with a sub-femtomolar dissociation constant (< 10−15 M) but does not bind at all to its amphibian homolog onconase (> 1 M). Extremely minor chemical changes such as the addition of a single methyl group to a binding partner can sometimes suffice to nearly eliminate binding; for example, the aminoacyl tRNA synthetase specific to the amino acid valine discriminates against the very similar side chain of the amino acid isoleucine. Proteins can bind to other proteins as well as to small-molecule substrates. When proteins bind specifically to other copies of the same molecule, they can oligomerize to form fibrils; this process occurs often in structural proteins that consist of globular monomers that self-associate to form rigid fibers.
First international unit of penicillin V (1959). One unit of penicillin V was defined as 0.590 micrograms of a reference standard held at Mill Hill in London. This unit is now obsolete. A similar standard was also established for penicillin K.
==== Doggie Kruger ==== Anubian Doggie Kruger (アヌビス星人ドギー・クルーガー, Anubisu Seijin Dogī Kurūgā), also known as "Boss" (ボス, Bosu) to several of his subordinates, is from Planet Anubis and is the tough-yet-honorable superintendent of the Space Police's Metropolitan Police, as well as chief of its Earth branch. While operating as a Dekaranger in his younger years, he earned a legendary reputation as "Hell's Guard Dog" (地獄の番犬, Jigoku no Banken), due in part to his willingness to do anything to save those he cares about. Despite this, he displays feelings for his assistant Swan and panics whenever he hears she has an admirer. During the events of the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After, Kruger investigated the alleged corruption of his superior Kight Reidlich, and was framed for murder and held captive for two years before his team rescues him in the present. Soon after, Kruger admits his feelings for Swan. In battle, Kruger is a practitioner of the Galaxy Sword-Style (銀河一刀流, Ginga Ittō-ryū) where he learned the style's secret technique, the Vega Impulse (ベガインパルス, Bega Inparusu). Though he is capable of destroying 100 foes without being defeated, he suffered from a spinal problem that caused him to miss once every 2000 attacks until being cured by chiropractor Yukito Sanjyo of the Abarangers. Additionally, utilizing a variant of the SP License called the Master License (マスターライセンス, Masutā Raisensu), Kruger can transform into the black-colored Deka Master (デカマスター, Deka Masutā).
Sources: en.wikipedia.org
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.
Both deliver the same active peptide and act on the same receptor. The tablet includes an absorption enhancer because peptides are poorly taken up intact from the gut. Bioavailability of the oral route is substantially lower, so the two are not dose-equivalent.
No, it is entirely synthetic and does not occur in nature. Native GLP-1 is produced in the gut and pancreas, but the analog is manufactured by chemical synthesis or recombinant methods. Traces of the analog are not expected in people who never received it.
冻融过程中冰晶形成与局部浓度升高会促使肽链发生界面吸附和聚集。聚集不仅降低有效含量，还会改变可见异物与不溶性微粒的计数结果。将溶液分装为单次使用的小体积等份可减少循环次数。